SOTIO’s research and development programmes embrace next-generation antibody-drug conjugate (ADC) oncology products, personalised cellular immunotherapy based on the CAR-T platform, and IL–15 superagonist-based treatments, including immunocytokines.
Since 2012, SOTIO has been validating the safety and efficacy of its products in comprehensive clinical trials conducted in Europe and the US.
In January 2025, SOTIO expanded its licensing collaboration with Biocytogen, a global biotechnology company advancing the research and development of novel antibody‑based therapies through innovative technologies. The company also exercised an option with Synaffix, a biotech firm offering a clinical‑stage platform for best‑in‑class antibody‑drug conjugates, bispecific antibodies, and other targeted therapeutics. This agreement further broadened the partnership to include two additional bispecific ADC candidates in SOTIO’s development pipeline.
SOTIO researchers presented promising preclinical results from two new attractive ADC programmes – SOT106 and SOT109 – at the prestigious annual conference of the American Association for Cancer Research (AACR). The company expects both programmes to advance to the clinical phase in 2026.
